Garret Adare FitzGerald MRIA FRS (born 11 May 1950) is an Irish physician.
He returned to Ireland in 1991 before relocating to the University of Pennsylvania in 1994 as the founding director of the Center for Experimental Therapeutics (CET).
[7] FitzGerald's work contributed substantially to the development of low-dose aspirin to prevent heart attacks and strokes.
[4] FitzGerald's lab was the first to predict and then mechanistically explain the cardiovascular hazard from Nonsteroidal anti-inflammatory drugs (NSAIDs), a common class of painkiller.
[8] His work showing that selective COX-2 inhibitors depress the production of prostacyclin in the endothelium, thereby increasing cardiovascular risk,[9] was instrumental in the withdrawal of Vioxx (rofecoxib) from the U.S. market in 2004.